Cardiac angiogenesis directed by stable Hypoxia Inducible Factor-1

Journal of Angiogenesis Research

Ralph V Shohet¹  Randall Z Allison¹  Joel T Outten¹  Cynthia D Anderson²  Jennifer Ecker¹  Chad B Walton¹ 

[1] Department of Medicine, University of Hawaii, Honolulu, HI 96813, USA;Department of Cellular and Molecular Biology, University of Hawaii, Honolulu, HI 96813, USA

关键词: Cardiac;    Perfusion;    Angiogenesis;    HIF-1;   

Others  :  801526
DOI  :  10.1186/2045-824X-5-15

 received in 2013-03-03, accepted in 2013-08-26,  发布年份 2013

【 摘 要 】

Background

The heterodimeric, oxygen-sensitive transcription factor Hypoxia Inducible Factor-1 (HIF-1) orchestrates angiogenesis and plays a key role in the response to ischemia and the growth of cancers.

Methods

We developed a transgenic mouse line in which expression of an oxygen-stable HIF-1α construct was controlled by a tetracycline-responsive promoter. HIF-1α expression was induced for up to 28 days in adult mouse heart, resulting in angiogenesis and progressive ventricular dysfunction.

Results

Gross inspection demonstrated enlarged hearts with large epicardial vessels with prominent side branches. Perfusion curves obtained by ultrasound contrast analysis demonstrated a significant increase in the myocardial red cell volume after 28 days of HIF-1α expression. Corrosion casts of cardiac vessels were made with a new low-viscosity resin that can fill the vasculature down to the level of the capillaries. Scanning electron microscopy of these casts reveal "lakes" of capillaries forming off of larger vessels after HIF expression, and support the rapid formation of mature neovascularization. Pro-angiogenic factors DLL-4, Notch-1, and PDGF-β, were evaluated by immunohistochemistry and Western blots, and support a pattern of progressive functional neoangiogenesis.

Conclusions

This study demonstrates the structural characteristics of HIF-directed angiogenesis and supports the utility of manipulation of HIF signaling to enhance perfusion and treat ischemia.

【 授权许可】

   
2013 Walton et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9(6):677-84.
• [2]Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92(12):5510-4.
• [3]Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE: Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A 1991, 88(13):5680-4.
• [4]Huang LE, Gu J, Schau M, Bunn HF: Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998, 95(14):7987-92.
• [5]Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-72.
• [6]Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295(5556):858-61.
• [7]Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM: An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996, 93(23):12969-73.
• [8]Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, Shohet RV: Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One 2010, 5(7):e11693.
• [9]Krucker T, Lang A, Meyer EP: New polyurethane-based material for vascular corrosion casting with improved physical and imaging characteristics. Microsc Res Tech 2006, 69(2):138-47.
• [10]Udaka K, Takeuchi Y, Movat HZ: Simple method for quantitation of enhanced vascular permeability. Proc Soc Exp Biol Med 1970, 133(4):1384-7.
• [11]Walton CB, Anderson CD, Boulay R, Shohet RV: Introduction to the ultrasound targeted microbubble destruction technique. J Vis Exp 2011., 52
• [12]Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S: Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998, 97(5):473-83.
• [13]Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132.
• [14]Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49(3):507-21.
• [15]Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999, 13(1):9-22.
• [16]Bunn HF, Poyton RO: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996, 76(3):839-85.
• [17]Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9):4604-13.
• [18]Giordano FJ, Johnson RS: Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001, 11(1):35-40.
• [19]Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J: Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 2004, 94(5):664-70.
• [20]Vincent KA, Feron O, Kelly RA: Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 2002, 12(8):362-7.
• [21]Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E: PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA 2008, 105(12):4745-50.